LCNB (NASDAQ:LCNB) reported quarterly earnings of $0.49 per share. This is a 25.64 percent increase over earnings of $0.39 per share from the same period last year.
FDA Approves LEQEMBI Under The Accelerated Approval Pathway For The Treatment Of Alzheimer’s Disease
Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™
Treatment with LEQEMBI should be initiated in patients with mild cognitive
